Mergers & Acquisitions - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 106 results

Roche to acquire Austrian next-generation antibody firm Dutalys

Roche to acquire Austrian next-generation antibody firm Dutalys

19-12-2014

Swiss pharma giant Roche has agreed to acquire Dutalys, a privately held biotechnology company based…

BiotechnologyDutalysDutaMabMergers & AcquisitionsOncologyRoche

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

Global oncology market to hit $109 billion in 2020

Global oncology market to hit $109 billion in 2020

26-11-2014

Cancer, with a death toll exceeding that of AIDS (acquired immune deficiency syndrome), tuberculosis…

AvastinCelgene Corp.GlobalMarkets & MarketingMergers & AcquisitionsNovartisOncologyPharmaceuticalResearchRevlimidRoche

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

Bristol-Myers enters option deal to acquire F-star Alpha and FS102

28-10-2014

US pharma major Bristol-Myers Squibb has entered into an agreement that provides it with the exclusive…

BiotechnologyBristol-Myers SquibbF-star AlphaFS102Mergers & AcquisitionsOncology

Sutro Biopharma and Celgene expand accord; add buyout option

23-10-2014

Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with…

BiotechnologyCelgene Corp.LicensingMergers & AcquisitionsOncologySutro Biopharma

Virax to acquire AKTivate and deep AKT inhibitor portfolio

17-10-2014

Australian biotechnology company Virax Holdings will acquire US oncology company AKTivate Therapeutics…

AKTivate TherapeuticsBiotechnologyMergers & AcquisitionsOncologyPathway OncologyVirax Holdings

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Prima BioMed to acquire Immutep for $28 million

Prima BioMed to acquire Immutep for $28 million

03-10-2014

France-based Immutep, a late-stage private biopharmaceutical company in the rapidly growing field of…

BiotechnologyFranceImmunologicalsImmutepMergers & AcquisitionsOncologyPrima BioMed

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Soligenix acquires Ph III-ready oncology clinical program

Soligenix acquires Ph III-ready oncology clinical program

05-09-2014

US clinical-stage biopharma firm Soligenix has acquired a novel orphan drug candidate, known as SGX301…

BiotechnologyhypericinMergers & AcquisitionsOncologySGX301Soligenix

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

Pfizer to acquire generics firm InnoPharma for up to $360 million

Pfizer to acquire generics firm InnoPharma for up to $360 million

17-07-2014

Having failed (so far) in its mega billion dollar ($116 billion) attempt to buy Anglo-Swedish drug major…

GenericsInnoPharmaMergers & AcquisitionsOncologyOphthalmicsPfizer

MabVax Therapeutics and Telik close merger

MabVax Therapeutics and Telik close merger

09-07-2014

USA-based MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a publicly-traded…

MabVax TherapeuticsMergers & AcquisitionsOncologyPharmaceuticalTelikUSA

Roche to acquire Seragon in deal that could reach over $1.7 billion

Roche to acquire Seragon in deal that could reach over $1.7 billion

02-07-2014

Swiss drug major Roche says its USA-based biotech subsidiary Genentech has entered into a definitive…

BiotechnologyGenentechMergers & AcquisitionsOncologyRocheSeragon Pharmaceuticals

BioAlliance and Topotarget progress merger plan

BioAlliance and Topotarget progress merger plan

01-07-2014

France-base BioAlliance Pharma and Denmark’s Topotarget say that the shareholders of both companies…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

SillaJen changes its name to mark Jennerex acquisition

20-06-2014

South Korean privately held pharma company SillaJen has changed its name to SillaJen Biotherapeutics…

Asia-PacificJennerexManagementMergers & AcquisitionsOncologyPexa-VecPharmaceuticalSillaJen

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

Celsion to acquire nucleic acid-based therapeutics firm EGEN

Celsion to acquire nucleic acid-based therapeutics firm EGEN

10-06-2014

US cancer drug developer Celsion Corp has entered into a definitive asset purchase agreement with EGEN,…

CelsionEGENMergers & AcquisitionsOncologyPharmaceutical

Definitive merger plan between BioAlliance Pharma and Topotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

22-05-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget have confirmed details of…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

1 to 25 of 106 results

Back to top